Compass Pathways Plc ADR(CMPS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:25 PM ET (Korea 9/12 05:25)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.62 | Insider Own | 1.61% | Shs Outstand | 138.5M | Perf Week | 7.98% |
| Market Cap | 1.99B | Forward P/E | - | EPS next Y | 26.18% | Insider Trans | - | Shs Float | 136.2M | Perf Month | 0.91% |
| Enterprise Value | 1.61B | PEG | - | EPS next Q | -0.36 | Inst Own | 64.8% | Short Float | 10.62% | Perf Quarter | 25.77% |
| Income | -0.41B | P/S | - | EPS this Y | 26.83% | Inst Trans | -2.66% | Short Ratio | 4.22 | Perf Half Y | 116.44% |
| Sales | 0.00B | P/B | 23.04 | EPS next 5Y | 27.55% | ROA | -102.08% | Short Interest | 14.47M | Perf YTD | 107.97% |
| Book/sh | 0.62 | P/C | 4.58 | EPS past 3/5Y | -12.71% -12.77% | ROE | -329.72% | 52W High | -9.58% ($15.87) | Perf Year | 173.85% |
| Cash/sh | 3.13 | P/FCF | - | Sales past 3/5Y | - | ROIC | -296.74% | 52W Low | 197.72% ($4.82) | Perf 3Y | 57.52% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -99.37% | Gross Margin | - | Volatility(W/M) | 7.38% 5.53% | Perf 5Y | -58.3% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.8 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.3 | EPS Q/Q | -352.05% | Profit Margin | - | RSI (14) | 56.06 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.3 | Sales Q/Q | - | SMA20 | 3.01% ($13.93) | Beta | 2.54 | Target Price | $23.35 |
| Payout | - | Debt/Eq | 0.65 | Earnings | 2026/8/5 | SMA50 | 9.31% ($13.13) | Rel Volume | 0.57 | Prev Close | $14.22 |
| Employees | 156 | LT Debt/Eq | 0.62 | EPS/Sales Surpr. | -384.41% - | SMA200 | 53.54% ($9.35) | Avg Volume(3M) | 3.43M | Price | $14.35 |
| IPO | 2020/9/18 | Option/Short | Yes/Yes | Trades | 16579 | Volume | 1,953,655 | Change | 0.91% |
Company
CMPS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A clinical-stage biotech company developing therapeutics for mental health disorders. It develops drug candidates using a differentiated therapeutic approach targeting mental health conditions such as treatment-resistant depression, and holds a lead candidate in late-stage clinical trials. Positioned as a growth-stage biotech targeting the underserved area of mental health, this stock is driven by business progress and market sentiment.
Over the past 1 year, on the higher side
10% below its 1-year high.
CMPS has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +26.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +57.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 64.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PSIL 0.11%
ARKG 0.02%
AADR 0.02%
SURI 0.02%
BBC 0.01%It ranks #4 in the industry
Based on market cap of $2B.
CMPS $2B PER -
HCA $92B PER 14.3
THC $21B PER 10.2
EHC $12B PER 19.8
FAQ
What kind of company is CMPS?
CMPS belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of CMPS?
The market cap of CMPS is approximately $2.0B, ranking 2,116 within its sector.
What is the 52-week high and low for CMPS?
CMPS has recorded a 52-week high of $15.87 and a low of $4.82.
